Tools   Select Another Resource Report Type

http://www.stroke.org/site/PageNavigator/NIHSS

The National Institutes of Health Stroke Scale (NIHSS) is a systematic assessment tool that provides a quantitative measure of stroke-related neurological deficit. The NIHSS was originally designed as a research tool to measure baseline data on patients in acute stroke clinical trials. Now, the scale is also widely used as a clinical assessment tool to evaluate acuity of stroke patients, determine appropriate treatment, and predict patient outcome. The NIHSS can be used as a clinical stroke assessment tool to evaluate and document neurological status in acute stroke patients. The stroke scale is valid for predicting lesion size and can serve as a measure of stroke severity. The NIHSS has been shown to be a predictor of both short and long term outcome of stroke patients. Additionally, the stroke scale serves as a data collection tool for planning patient care and provides a common language for information exchanges among healthcare providers. Performing the scale takes between 5-8 minutes. Emergency physicians and nurses, neurologists, neuroscience nurses and other stroke team members are typical examples of who should be certified to perform the NIHSS. The NINDS/NIH training and testing DVD can be obtained from the National Institute of Neurological Disorders and Stroke. Sponsors: NIHSS is supported by the National Institute of Neurological Disorders and Stroke (NINDS).

Proper citation: National Institutes of Health Stroke Scale (RRID:SCR_001804) Copy   

•   Source: SciCrunch Registry

http://22q13.org/j15/

The Phelan-McDermid Syndrome Foundation, established in 2002, is a 501(c)3 nonprofit group that provides support services for those who have family members affected by 22q13 Deletion Syndrome / Phelan-McDermid Syndrome. It also raises money to further awareness of the syndrome through research and sponsoring an international conference every two years that brings together families, researchers and therapists. The Foundation facilitates connections between families through networking, communications and support services. We also build alliances with other rare diseases groups to expand our reach and exposure. The syndrome, which affects families worldwide, is a rare genetic occurrence and is the result of a damaged or missing protein on the 22nd chromosome. Our Foundation works with researchers who are looking into the cause and possible cure for the syndrome. PMSF's grants and fellowships program is intended to encourage research projects that will advance the development of treatments and cures for PMS. Our mission is to bring together everyone affected by 22q13 Deletion Syndrome/Phelan-McDermid Syndrome to help them through the challenges they face every day and to raise awareness in the medical and research communities.

Proper citation: Phelan-McDermid Syndrome Foundation (RRID:SCR_001707) Copy   

•   Source: SciCrunch Registry

http://www.cimit.org/

A non-profit consortium of Boston academic medical centers and universities (and growing) to accelerate the healthcare innovation cycle by fostering interdisciplinary, inter-institutional collaboration among experts in translational research, medicine, science, engineering, healthcare implementation and entrepreneurship in concert with industry, foundations and government to rapidly improve patient care. It concentrates on early stage, high-risk ideas, projects and supports them through to a commercial exit from academia. It provides innovators with resources to explore, develop and implement novel technological solutions for today's most urgent healthcare problems. CIMIT is dedicated to helping develop medical technology that will help both military and civilian patients.

Proper citation: Center for Integration of Medicine and Innovative Technology (RRID:SCR_003710) Copy   

•   Source: SciCrunch Registry

http://c3nproject.org/

Project designing, prototyping, optimizing, and evaluating a learning health system to improve clinical practice, patient self-management, and disease outcomes of patients with chronic illness. This open, peer production system combines the collective input of patients, clinicians and researchers. It combines large clinical data registries with patient entered data and makes them accessible and interactive. A platform allows researchers to design, test and implement new knowledge and innovations in patient care. To test their platform approach, C3N is working on a model of treating children with Inflammatory Bowel Disease using the ImproveCareNow Network of pediatric clinics. Following this demonstration phase, the goal is to apply the social, scientific and technical platform to transform the care of a variety of chronic illnesses. The C3N effort has the following goals: # Deploy and optimize an integrated set of engagement tools to make it easier for patients and care providers to collect and use the right information during the clinical encounter and in between visits. # Prototype novel interventions to re-design care delivery by promoting the development of tools for real-time and dynamic population management, "just-in time" scheduling of visits, virtual clinic visits, and measuring the impact of these interventions on health, care, and cost. # Pilot and deploy patient-focused technology to improve the flow of data between patients, clinicians and scientists to enable faster learning and improvement.

Proper citation: Collaborative Chronic Care Network (RRID:SCR_003708) Copy   

•   Source: SciCrunch Registry

http://cptrinitiative.org/

A collaboration of international pharmaceutical companies, public health experts, civil society organizations, and U.S., European, and other regulatory authorities to speed the development of new and improved drug regimens for tuberculosis (TB). Its goals include creating innovative tools, including TB data standards and databases. The Initiative is built around four operating arms: Regulatory Science Consortium, Drug Development Coalition, Research Resources Group, and Drug Susceptibility Testing Group. The focus of the consortium is to: * Develop and integrate data standards * Qualify biomarkers through the Food and Drug Administration (FDA) / European Medicines Authority (EMA) * Develop quantitative disease progression (natural history) models * Create disease response metrics, develop target product profiles and supporting assays, and * Develop new pharmacokinetic/dynamic measures of drug interactions Accomplishments include: * Engaged the FDA, which has released updated regulatory guide-lines for developing new TB drug regimens with efforts to create a more favorable environment for combination regimen development * TB Alliance launched the first-ever clinical trial of a novel combination drug regimen for TB, validating the approach to regimen development set forth by CPTR, and is moving to a phase III clinical trial named STAND. * Developed and published TB data standards in collaboration with the Clinical Data Interchange Standards Consortium (CDISC). * Expanded scope to include the CPTR Rapid Drug Susceptibility Testing (RDST) Consortium and an expanded Modeling and Simulation development program. * Pursued several regulatory pathways with the FDA for the Hollow Fiber System Model for TB (HFS-TB). * Submitted a dossier to the EMA on the HFS-TB for qualification opinion consideration. * Submitted a "briefing book" to the FDA via the pre-IND process to review CPTR's data analysis plan and data inventory for liquid culture, with emphasis on time-to-positivity, as a quantitative measure of long-term outcome. * Initiated planning to develop a database supporting the RDST Consortium's goal to develop a rapid TB drug susceptibility test.

Proper citation: Critical Path to TB Drug Regimens (RRID:SCR_003698) Copy   

•   Source: SciCrunch Registry

http://www.imidia.org/

Consortium aiming to improve pancreatic beta-cell function and identification of diagnostic biomarkers for treatment monitoring in diabetes. It brings together academic teams, pharmaceutical companies, and a Small to Medium Enterprises (SMEs), which provides a unique blend of expertise and forms a strong basis for a successful enterprise to ultimately improve industrial competitiveness and Public Health in Europe. The program aims at delivering: * Novel tools for the study of human beta-cell development, function and survival; their modulation by potential therapeutic compounds; and for in vivo beta-cell imaging. * Biomarkers for the diagnosis and prognosis of beta-cell failure and for monitoring diabetes progression and treatment. * Knowledge on novel molecular pathways and sites that control beta-cell life & death as well as mass and function.

Proper citation: IMIDIA (RRID:SCR_003865) Copy   

•   Source: SciCrunch Registry

http://www.lyonbiopole.com/index-en.html

A worldwide competitiveness cluster centered on pharmaceutical activities including the fight against human and animal infectious diseases and cancers. Designed as a tool interface and public / private approximation, the division has implemented measures to encourage collaborative R & D, help in setting up projects and find funding, increase strategic and financial partnerships for economic development and international companies, provide access to reception areas, technological shared platforms such as the Infectious Diseases Center Lyonbiop��le. It aims to strengthen the competitiveness of the sector health and the attractiveness of the Rh��ne-Alpes area, mainly on the Lyon-Grenoble axis. (adapted from the translated Wikipedia)

Proper citation: Lyonbiopole (RRID:SCR_003733) Copy   

•   Source: SciCrunch Registry

http://etoh.niaaa.nih.gov/

Portal to support researchers and practitioners searching for information related to alcohol research including links to a number of databases, journals, and Web sites focused on alcohol research and related topics. Also included is a link to the archived ETOH database, the premier Alcohol and Alcohol Problems Science Database, which contains over 130,000 records and covers the period from 1972 through 2003. Included in ETOH are abstracts and bibliographic references to journal articles, books, dissertation abstracts, conference papers and proceedings, reports and studies, and chapters in edited works. ETOH's scope reflects the multidisciplinary nature of the alcohol research field. The range of subject areas contained in ETOH includes: medicine, biochemistry, psychology, psychiatry, epidemiology, sociology, anthropology, treatment, prevention, education, accidents and safety, legislation, criminal justice, public policy, and health services research. The ETOH database is indexed with vocabulary from the Alcohol and Other Drug Thesaurus: A Guide to Concepts and Terminology in Substance Abuse and Addiction (AOD Thesaurus), Third Edition. More than 5,000 terms in the AOD Thesaurus are used as ETOH descriptors. The Databases/Resources section includes databases and resources for alcohol researchers and practitioners. It includes an introduction to the National Library of Medicine's PubMed and some sample searches on alcohol to run in the PubMed database; descriptions of and links to the various databases of the National Clearinghouse for Alcohol and Drug Information (NCADI); a selection of alcohol and other drug databases with their descriptions and links; links to peer-reviewed journals most often used by alcohol researchers; and links to a selection of Web sites pertinent to the substance abuse field.

Proper citation: Alcohol and Alcohol Problems Science Database (RRID:SCR_003768) Copy   

•   Source: SciCrunch Registry

http://www.hms.harvard.edu/NEPRC/

THIS RESOURCE IS NO LONGER IN SERVICE. Documented on May 12,2023. A center that focuses on performing bio-medical research on nonhuman primates to aid in human health research. The center also focuses on training young scientists for professional careers in bio-medical research and primate biology. One of the New England Primate Research School's main accomplishments was the creation of an animal model for AIDS that first demonstrated that vaccine protection could be possible. Recent research has led to the development of novel agents for brain imaging that will aid in the diagnosis and treatment of Parkinson's disease.

Proper citation: New England Primate Research School (RRID:SCR_008290) Copy   

•   Source: SciCrunch Registry

http://www.neuro-center.com/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on July 08, 2014. A multi-disciplinary institute providing specialized diagnostic evaluations, innovative treatments, education and research. It provides a collaborative, team-centered approach to provide innovative diagnostics to assist in developing cutting-edge brain based interventions and treatment strategies to best serve their patient's individual needs. Comprehensive Neuroscience Center is dedicated to working with children and adults who demonstrate neurodevelopmental disorders such as Autism Spectrum Disorders, Attention Deficits Hyperactivity Disorder, Learning Disabilities and Language-based deficits, as well as other neurological-based disorders including Traumatic brain injury, Disorders of Consciousness, Disorders of Aging, Alzheimer's and Dementia.

Proper citation: Comprehensive Neuroscience Center (RRID:SCR_008705) Copy   

•   Source: SciCrunch Registry

http://cbdb.nimh.nih.gov/

THIS RESOURCE IS NO LONGER IN SERVICE, documented on February 07, 2013. A multidisciplinary neuroscience laboratory in which basic and clinical scientists work side by side exploring neural mechanisms and models of mental and cognitive function and of neuropsychiatric illness. Experiments are performed at many levels of inquiry, from basic molecular biology of the gene to clinical examinations of patients. A major area of investigation of this laboratory is the genetic mechanisms implicated in the pathogenesis of schizophrenia and its treatment. The laboratory is organized as a multi-disciplinary team of investigators with a common mission: to identify and fully characterize basic genetic and neurobiological mechanisms of schizophrenia and related cognitive and emotional disorders. The various components of this effort are centered various different units or divisions represented by groups of investigators, at various levels of training and experience, working on related experiments. The Director of the Branch and of the Genes, Cognition and Psychosis Program (GCAP) is Daniel R. Weinberger, M.D. The CBDB is the principle research laboratory in the created (2003) Genes, Cognition, and Psychosis Program (GCAP) of the NIMH. After twelve years of residing on the pastoral grounds of St. Elizabeths Hospital, in Southeast Washington, CBDB moved back to the main NIH campus in Bethesda, Maryland in 1998. While the unique setting of St. Elizabeths is irreplaceable, we have occupied beautiful new laboratories and clinic spaces that were created for us, and we are in the mainstream of NIH life.

Proper citation: NIMH Intramural Research Program Clinical Brain Disorders Branch (RRID:SCR_008728) Copy   

•   Source: SciCrunch Registry

http://www.msmc.com/neurosciences/wien-center-for-alzheimers-disease-memory-disorders

A joint program between Mount Sinai Medical Center and the University of Miami Department of Psychiatry that seeks an end to Alzheimer's disease and similar disorders through research, diagnosis, education and treatment. The goals are to improve memory and mental responsiveness of Alzheimer's patients, delay the onset of the disease and, ultimately, find a cure. The Wien Center typically conducts multidisciplinary initiatives utilizing clinical trials.

Proper citation: Wien Center For Alzheimer's Disease and Memory Disorders (RRID:SCR_008755) Copy   

•   Source: SciCrunch Registry

http://depts.washington.edu/adrcweb/

Research center investigating the basic mechanisms underlying the development of Alzheimer's disease and related disorders, directing particular attention to biomarkers and experimental new treatments. They also continue to search for genetic risk factors underlying Alzheimer's disease (AD). Their main priorities are to find causes, effective treatments, and prevention strategies. Their investigators also are partnering with other Alzheimer's Centers across the country to evaluate promising new medications and other treatments for AD. The ultimate goal of their basic and clinical studies is to improve patient care and function, and improve the quality of life for both the patient and the caregiver. ADRC Cores: * Administration * Clinical Core * Satellite Core * Data Management & Biostatistics * Neuropathology Core * Education & Information Transfer * Genetics

Proper citation: University of Washington Alzheimers Disease Research Center (RRID:SCR_008814) Copy   

•   Source: SciCrunch Registry

http://www.utsouthwestern.edu/education/medical-school/departments/neurology/programs/alzheimers-disease-center/index.html

A center dedicated to discovering treatments and providing preventative measures for Alzheimer's Disease. Research is strongly focused on brain changes in regards to healthy aging, mild cognitive impairment and other disorders, such as dementia. It aims to improve diagnostic measures and care giving techniques, discover more effective medical interventions, and understand the etiology of the disease and find an eventual cure. The center provides diagnostic evaluations of adult memory problems, as well as the opportunity to participate in clinical research to aid in finding better Alzheimer's treatments.

Proper citation: University of Texas Southwestern Medical Center - Alzheimer's Disease Center (RRID:SCR_008836) Copy   

•   Source: SciCrunch Registry

http://www.nimh.nih.gov/funding/clinical-trials-for-researchers/practical/tordia/treatment-of-ssri-resistant-depression-in-adolescents-tordia.shtml

A multi-site, clinical research study examining treatment options for teens whose depression has not improved after one adequate trial of a selective serotonin reuptake inhibitor (SSRI), a type of antidepressant. The purpose of the study is to determine how best to treat adolescents with depression that is resistant to the first SSRI antidepressant they have tried. Participants receive one of three other antidepressant medications, either alone or in combination with cognitive behavioral therapy. The TORDIA study aims to develop useful clinical guidelines for the care and management of adolescent depression. Adolescents ages 12 to 18, currently taking a prescribed selective serotonin reuptake inhibitor (SSRI) and still experiencing depression, participate in a 12-week randomized treatment study that includes one of four conditions: (1) switching to an alternative SSRI, (2) switching to a different non-SSRI antidepressant, (3) switching to an alternative SSRI and receiving cognitive behavioral therapy (CBT), or (4) switching to a different non-SSRI antidepressant and receiving CBT. This is a double-blind study, which means that neither the participant nor the clinical staff will know which of the three possible medications has been assigned. Participants who respond to the assigned treatment will receive 12 additional weeks of the same treatment. Those who do not appear to be getting better will be offered 12 weeks of an alternative, individualized treatment plan based on each participant''s particular needs. All participants will receive follow-up psychiatric evaluations for 12 months after the 12-week continuation phase of the study, regardless of treatment adherence. For more information visit, http://www.clinicaltrials.gov/ct2/show/NCT00018902?term=clinical+trial+AND+treatment+of+ssri-resistant+AND+depression+AND+TORDIA+AND+study&rank=1

Proper citation: Treatment of SSRI-resistant Depression in Adolescents (TORDIA) (RRID:SCR_008831) Copy   

•   Source: SciCrunch Registry

http://www.medschool.lsuhsc.edu/epilepsy_center/

The LSU Epilepsy Center of Excellence is dedicated to providing state-of-the-art, comprehensive epilepsy treatment, enhancing access to epilepsy education for patients and physicians, and promoting multidisciplinary epilepsy research in pharmacology, neuroelectrophysiology, neuroimaging, neurosurgery, neuropsychology, biomedical engineering and public health. The center''s team of professionals offers diagnostic and presurgical monitoring, the strategic use of antiepileptic medications, specialized epilepsy neuroimaging, vagus nerve stimulator implantation, ketogenic diet management, neuropsychological testing, psychiatric support and epilepsy surgery for adults and children. The Center also hosts several clinical research trials each year for investigational medications and devices. The following are the treatment methods currently available at this center: - Epilepsy Brain Implants - Responsive Neurostimulator (RNS) - Medications - Medication blood level monitoring - Vagus Nerve Stimulators (VNS) - Epilepsy Surgery - Ketogenic Diet - Psychiatric Services - Radiosurgery Epilepsy Center Sections: *Electrophysiology *Neuroimaging *Neuropsychology *Neuroscience *Neurosurgery *Pharmacology *Psychiatry *Research

Proper citation: Louisiana State University School of Medicine, Health Sciences Center: Epilepsy Center (RRID:SCR_006519) Copy   

•   Source: SciCrunch Registry

https://jhuccs1.us/gpcrc/

Perform clinical, epidemiological, and therapeutic research in gastroparesis and provide an infrastructure that can rapidly and efficiently design and conduct clinical trials for effective medical, surgical, or other interventions to improve treatment of patients with gastroparesis. The GpCRC studies comprise well characterized individuals with diabetic, surgical, and idiopathic gastroparesis.

Proper citation: Gastroparesis Clinical Research Consortium (RRID:SCR_006673) Copy   

•   Source: SciCrunch Registry

http://obssr.od.nih.gov/index.aspx

An NIH office devoted to the study of the role of behavioral and social factors in illness and health. Its mission is to stimulate behavioral and social sciences research throughout NIH and to integrate these areas of research more fully into others of the NIH health research enterprise, thereby improving our understanding, treatment, and prevention of disease. To provide the OBSSR with counsel in fulfilling its mission, the Behavioral and Social Sciences Research Coordinating Committee (BSSR CC) serves as an internal advisory board. The Office of Behavioral and Social Sciences Research (OBSSR) opened officially on July 1, 1995. The major responsibilities of the office and its director, set forth in its formal mission statement, are: * To provide leadership and direction in the development, refinement, and implementation of a trans-NIH plan to increase the scope of and support for behavioral and social sciences research. * To inform and advise the NIH director and other key officials of trends and developments having significant bearing on the missions of the NIH, DHHS, and other federal agencies. * To serve as the principal NIH spokesperson regarding research on the importance of behavioral, social, and lifestyle factors in the causation, treatment, and prevention of diseases; and to advise and consult on these topics with NIH scientists and others within and outside the federal government. * To develop a standard definition of behavioral and social sciences research, assess the current levels of NIH support for this research, and develop an overall strategy for the uniform expansion and integration * of these disciplines across NIH institutes and centers. * To develop initiatives designed to stimulate research in the behavioral and social sciences arena, integrate a bio-behavioral perspective across the research areas of the NIH, and encourage the study of behavioral and social sciences across NIH''s institutes and centers. * To initiate and promote studies to evaluate the contributions of behavioral, social, and lifestyle determinants in the development, course, treatment, and prevention of illness and related public health problems. * To provide leadership in ensuring that findings from behavioral and social sciences research are disseminated to the public. * To sponsor seminars, symposia, workshops, and conferences at the NIH and at national and international scientific meetings on state-of-the-art behavioral and social sciences research. Funding Opportunities Announcements (FOA) Since opening its doors in 1995, The Office of Behavioral and Social Sciences Research (OBSSR) has worked to achieve the goals of its authorizing legislation by effectively highlighting and supporting the scientific opportunities that exist in basic and applied behavioral and social sciences research. Guided by its Strategic Plan, OBSSR has been working actively with its IC partners to develop funding opportunities in the behavioral and social sciences. Although OBSSR does not have grant-making authority, it has been active in organizing and funding (through transfers to NIH Institutes and Centers) a variety of trans-NIH research programs. Scientific Areas The Office of Behavioral and Social Sciences Researchs (OBSSR) leadership is crucial at a time when exciting scientific opportunities, persistent public health needs, and emergent public health challenges face our nation. The vision of the office is to bring together the biomedical, behavioral, and social science communities to work more collaboratively to solve complex pressing health challenges. Notable areas of research where OBSSR has led efforts and encourages research include: * Biopsychosocial Interactions * Methodology (including Systems Science and CBPR) * Genes, Behavior and Environment * Social and Cultural Factors in Health * Health and Behavior * Translation OBSSR Training & Education Opportunities The Office of Behavioral and Social Sciences Research (OBSSR) develops and coordinates training and career development opportunities with the NIH Institutes and Centers.

Proper citation: Office of Behavioral and Social Sciences Research (RRID:SCR_006554) Copy   

•   Source: SciCrunch Registry

http://cancercontrol.cancer.gov/tcrb/tturc/

A transdisciplinary approach to the full spectrum of basic and applied research on tobacco use to reduce the disease burden of tobacco use, including: * Etiology of tobacco use and addiction * Impact of advertising and marketing * Prevention of tobacco use * Treatment of tobacco use and addiction * Identification of biomarkers of tobacco exposure * Identification of genes related to addiction and susceptibility to harm from tobacco Goals * Increase the number of investigators from relevant disciplines who focus on the study of tobacco use as part of transdisciplinary teams. * Generate basic research evidence to improve understanding of the etiology and natural history of tobacco use. * Produce evidence-based tobacco use interventions that can translate to the community and specific understudied or underserved populations. * Increase the number of evidence-based interventions that are novel, including the development, testing and dissemination of innovative behavioral treatments and prevention strategies based upon findings from basic research. * Train transdisciplinary investigators capable of conducting cutting-edge tobacco use research. * Increase the number of peer-reviewed publications in the areas of tobacco use, nicotine addiction, and treatment.

Proper citation: Transdisciplinary Tobacco Use Research Centers (RRID:SCR_006858) Copy   

•   Source: SciCrunch Registry

http://www.medschool.lsuhsc.edu/psychiatry/

The LSU Department of Psychiatry is committed to the finest quality medical student education, post-medical school training for residents and fellows in all aspects of psychiatry: general psychiatry, infant, child and adolescent psychiatry, emergency and administrative psychiatry, and consultation liaison psychiatry. This department also provides excellent graduate and post-graduate training in social work and psychology. The department provides major leadership in research spanning our field and makes important advances in the understanding of psychopharmacology and neuroscience, developmental disorders, psychodynamic psychiatry, and treatment of children and families exposed to community and family violence. It plays key roles related to transmission and treatment of HIV infection, prevention of school failure and incarceration among high risk youth and maintaining mental health in our senior citizens, to name but a few areas. Their nationally recognized Harris Infant Mental Health Center trains professionals in several states to understand and treat the most vulnerable of our children and their families during the first three years of life. The Harris Center for Infant Mental Health of the LSUHSC Department of Psychiatry is devoted to the study and treatment of infants and young children. The goals of the Center are: - To develop a crucial number of mental health professionals locally, nationally, and internationally trained to evaluate and treat infants. - To develop networks to provide support for individuals working with infants. - To bring together individuals from different mental health disciplines who will have a core set of skills and knowledge to assess and treat infants. - To develop expertise in evaluation and treatment for high-risk infants. - To educate the judges, lawyers and court personnel on the effects of violence on young children.

Proper citation: Louisiana State University School of Medicine, Health Sciences Center: Department of Psychiatry (RRID:SCR_012940) Copy   

•   Source: SciCrunch Registry